Scientific Programme
Thursday, 30 November 2023
Virtual
15:00 - 15:10 CET
Welcome and IntroductionSchnell O (Munich, Germany)
15:10 – 16:50 CET
Update on Clinical Guidelines and network Meta-AnalysesChair: Groop P-H (Helsinki, Finland), Rydén L (Stockholm, Sweden)
15:10 – 15:25
Management of CKD in 2023: an update of guidelinesGroop P-H (Helsinki, Finland)
15:25 – 15:40
What`s new in the ESC “Diabetes and the Heart” and “Heart Failure” Guidelines 2023Marx N (Aachen, Germany)
15:40 – 15:50
Discussion
15:50 – 16:05
Treatment for Type 2 Diabetes: systematic review and network meta-analysis for the creation of living guidelinesRydén L (Stockholm, Sweden)
16:05 – 16:20
Join the Alliance for Living Evidence (Alive)!Tendal Jeppesen B (Copenhagen, Denmark)
16:20 – 16:35
Strengthening the recognition of minority groups in clinical guidelines for diabetesGavin JR (Atlanta, USA)
16:35 – 16:50
Discussion
16:50 – 17:00 CET
Break
17:00 – 18:30 CET
Making sense of Patient-Reported Outcomes (PROs) and why they matterChair: Barnard-Kelly K (Hampshire, UK), Lalic N (Belgrade, Serbia)
17:00 – 17:15
Consensus statement on PROs - why, how and what does it matter?Barnard-Kelly K (Hampshire, UK)
17:15 – 17:30
IDF perspective on PROsSchwarz P (Dresden, Germany)
17:30 – 17:45
PROs: What are governments doing in this space and how do they influence policy?Taylor B (Tampa, USA)
17:45 – 18:00
Patient´s perspectives on PROsHuntley G (Indianapolis, USA)
18:00 – 18:30
Discussion
18:30 – 18:45 CET
Break
18:45 – 19:45 CET
Keynote lectures: Overcoming boundaries - new options ariseChair: Giorgino F (Bari, Italy), Schumm-Draeger P (Munich, Germany)
18:45 – 19:05
Multireceptor drugs for obesity: a new emerging universeMüller T (Munich, Germany)
19:05 – 19:15
Discussion
19:15 – 19:35
New horizons for CGM in diabetes: further building a key pillar of diabetes managementBattelino T (Ljubljana, Slovenia)
19:35 – 19:45
Discussion
19:45 – 20:45 CET
Oral Presentations – Part 1Chair: Mankovsky B (Kyiv, Ukraine), Schnell O (Munich, Germany)
OP 1: Lipid-Lowering Treatments and Risk of Cardiovascular Events in Over 9000 Patients From 14 European Countries: 1-year Prospective Follow-Up of the SANTORINI RegistryAguiar C (Carnaxide, Portugal)
OP 2: Benefit of Dual Therapy With GLP-1 RA and SGLT2i on Cardiovascular Outcomes in Type 2 DiabetesKvist K (Søborg, Denmark)
OP 3: Tirzepatide Reduces Albuminuria in Patients With Type 2 Diabetes: Post-Hoc Pooled Analysis of SURPASS 1-5Ranta K (Helsinki, Finland)
OP 4: Impact of Finerenone on Chronic Kidney Disease Progression in Chinese Patients With Type 2 Diabetes: FIGARO-DKD Subgroup AnalysisBrinker M (Wuppertal, Germany)
OP 5: A cross-sectional survey on CKD diagnosis and managementRötzer R (Munich, Germany)
20:45 CET
Closing of Day 1
Friday, 01 December 2023
Virtual
08:30 – 09:50 CET
Prevention of Type 1 Diabetes and its complicationsChairs: Hummel M (Munich, Germany), Malik RA (Doha, Qatar)
08:30 – 08:45
Type 1 Diabetes: early detection and preventive approachesLarsson HE (Lund, Sweden)
08:45 – 09:00
Teplizumab – Delaying the onset of Type 1 DiabetesMathieu C (Leuven, Belgium)
09:00 – 09:15
Treatment strategies for neuropathy in Type 1 DiabetesTesfaye S (Sheffield, UK)
09:15 – 09:30
Preventing and delaying the progression of chronic kidney disease (CKD) in Type 1 Diabetes Groop P-H (Helsinki, Finland)
09:30 – 09:50
Discussion
09:50 – 10:00 CET
Break
10:00 – 11:15 CET
Identification of chronic kidney disease to guide therapeutic decisionChairs: Topsever P (Istanbul, Turkey), Ji L (Bejing, China)
in cooperation with PCDE
10:00 – 10:15
Self-rated knowledge and competence regarding the management of chronic kidney disease in primary careTopsever P (Istanbul, Turkey)
10:15 – 10:30
Shaping the role of primary care in diagnosis of CKD Itzhak B (Haifa, Israel)
10:30 – 10:45
Identifying people with CKD in primary care: the role of POCT in KDIGO GuidelinesJacob S (Villingen-Schwenningen, Germany)
10:45 – 11:00
Diagnosing CKD with UACR in China - Paving the Way for Effective TreatmentYu X (Tongji, China)
11:00 – 11:15
Discussion
11:15 – 11:30 CET
Break
11:30 – 12:30 CET
Current considerations in the management of CKDChair: Heerspink H (Groningen, Netherlands), Fernández-Fernández B (Madrid, Spain)
11:30 – 11:50
SGLT-2 inhibitors in CKD: new outcomes to strengthen the bridge to clinical careHeerspink H (Groningen, Netherlands)
11:50 – 12:10
Non-steroidal MRAs: recent and future perspectivesRossing P (Copenhagen, Denmark)
12:10 – 12:30
Discussion
12:30 – 13:15 CET
Heart failure and Cardiovascular RiskChair: Ceriello A (Milan, Italy), Škrha J (Prague, Czech Republic)
12:30 – 12:45
Current and future aspects of heart failure managementKosiborod M (Kansas City, USA)
12:45 – 13:00
CLEAR Outcomes: Reducing cardiovascular mortality and morbidity with bempedoic acidRay KK (London, UK)
13:00 – 13:15
Discussion
13:15 – 13:45 CET
Break
13:45 – 14:30 CET
Cancer – an emerging, yet largely underrecognized important topic in metabolic diseasesChair: Ceriello A (Milan, Italy), Ibrahim M (Charlotte, USA)
13:45 – 14:00
Type 2 Diabetes & Cancer Standl E (Munich, Germany)
14:00 – 14:15
Obesity & Cancer Herzig S (Munich, Germany)
14:15 – 14:30
Discussion
14:30 – 16:15 CET
Diabetes, Obesity and NASH – Discovering the New NowChairs: Forst T (Mainz, Germany), Rodbard H (Rockville, USA)
14:30 – 14:50
Recent advances in incretin therapyFrias P (Los Angeles, USA)
14:50 – 15:10
Successful treatment of Type 2 Diabetes and obesity: managing cardiovascular risk and implementing new treatment pathwaysVilsbøll T (Copenhagen, Denmark)
15:10 – 15:30
Diagnosis, prognosis and future treatments options of fatty liver disease Tacke F (Berlin, Germany)
15:30 – 15:50
How to communicate successfully with people who are obeseSnoek F (Amsterdam, Netherlands)
15:50 – 16:15
Discussion
16:15 – 16:30 CET
Break
16:30 – 17:30 CET
Industry´s perspective - panel discussion
17:30 – 18:30 CET
Oral Presentations – Part 2Chair: Forst T (Mainz, Germany), Mankovsky B (Kyiv, Ukraine)
OP 6: Change in Fibrosis-4 Index (FIB4) is Associated With Risk of Liver Events, Cardiovascular Events, and All-Cause Mortality in Patients With Obesity and/or Type 2 Diabetes (T2D)Jara M (Søborg, Denmark)
OP 7: Prevalence and Effect of Semaglutide on Non-Alcoholic Steatohepatitis in People With Obesity With and Without Type 2 Diabetes: Analyses From the STEP 1 and 2 Trials Using SomaSignal TestsLong M (Søborg, Denmark)
OP 8: Heart Failure in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease With and Without Cardiovascular Autonomic NeuropathyMonashnenko O (Kyiv, Ukraine)
OP 9: Glycaemic Control in Users of Automated Insulin Delivery Systems Increased Slightly From 2019 to 2021: Longitudinal Data of the Digitalisation and Technology ReportEhrmann D (Bad Mergentheim, Germany)
OP 10: Real-World Evidence Showing Sustained Improvements in Glycemia at 1 Year in People With Type 2 Diabetes Using the OneTouch Reveal® Mobile App With OneTouch® Blood Glucose MetersHolt E (Malvern, USA)
18:30 – 18:45 CET
Abstract Awards and ClosingSchnell O (Munich, Germany)